RA
Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
$40.45 -5.93% (-$2.55)
1M -18.00%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9Valuation
21 /100
Expensive P/S 100.32x
P/B 4.74x
P/E N/A
Growth
100 /100
Growing Book val. growth 191.81%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 685.80%
FCF margin 485.75%
Quality
1 /100
Poor ROIC 35.45%
ROE 29.02%
Asset turnover 0.04x
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 15.72x
Int. coverage N/A
Stability
31 /100
Unstable Beta 1.03x
EPS volatility 169.43%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RAPP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abraham N. Ceesay
Employees
84
Headquarters
Boston
Upcoming events
05 NOV
Earnings
Upcoming earnings report